Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis
Lab / animal
OA: closed
AI-generated summary
DU-6859a significantly reduced viable cell counts of Escherichia coli and Bacteroides fragilis in a rat model of uterine endometritis, demonstrating efficacy comparable to levofloxacin.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We evaluated the efficacy of a new quinolone, DU-6859a, using a new model of rat uterine endometritis. Rats were infected with mixed inocula of Escherichia coli and Bacteroides fragilis. The MICs of DU-6859a and levofloxacin against E. coli were 0.025 and 0.05 mg/L, respectively; those against B. fragilis were 0.20 and 0.39 mg/L, respectively. Immediately after inoculating 10(5) cfu/rat of each organism, DU-6859a or levofloxacin (20 mg/kg po bid or tid, respectively, for 3 days) was administered and compared with the untreated group. The viable cell counts of E. coli and B. fragilis in the DU-6859a- and levofloxacin-treated groups were significantly lower than those in the untreated group. These results suggest that DU-6859a would be useful for treating polymicrobial infections in uterine endometritis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-18T09:30:06.152893+00:00
- pubmed
- last seen: 2026-10-08T22:00:35.617750+00:00
- unpaywall
- last seen: 2026-10-20T06:27:24.728081+00:00